Ladenburg Thalmann Upgrades Ardelyx to 'Buy' with $16 Target
Ladenburg Thalmann sees upside in Ardelyx, Inc., setting a $16 price target.
Key Points
- Ladenburg Thalmann upgraded Ardelyx, Inc. (NASDAQ: ARDX) to a 'buy' rating with a $16 price target on June 16, 2026.
- Ladenburg Thalmann's $16 price target implies 151.18% upside from Ardelyx, Inc.'s ($ARDX) current $6.37 share price.
- Ardelyx shares were trading around $5.69, with a market cap of $1.4 billion and a forward P/E of 11.04.
- Insider sales occurred on May 21, 2026, involving several executives, with no insider purchases reported.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Ladenburg Thalmann has upgraded its rating on Ardelyx, Inc. (NASDAQ: ARDX) to 'buy', setting a price target of $16. The announcement was made on June 16, 2026, reflecting confidence in Ardelyx's growth potential. Shares of Ardelyx recently traded at around $5.69.
Analysts Set New Price Targets
Ladenburg Thalmann's analyst Caroline Palomeque assumed coverage with a 'buy' rating, targeting $16 per share. Other analysts have also shown optimism. On February 20, 2026, HC Wainwright & Co. maintained a 'buy' rating with an $18 target. Earlier in January, Wedbush and Citigroup maintained their 'buy' ratings with targets of $19 and $14, respectively. Piper Sandler upgraded the stock to 'buy' with a $16 target on January 9, 2026.
Ardelyx, Inc. Stock Up 67.2%
Shares of Ardelyx, Inc. on the NasdaqGM hovered around $5.69. The company has a market capitalization of $1.4 billion and a forward P/E ratio of 11.04. Ardelyx's beta is 0.576, indicating lower volatility compared to the market. The 52-week trading range is between $3.49 and $8.40, with a 50-day moving average of $6.16 and a 200-day moving average of $6.12. The company maintains a current ratio of 3.49 and a quick ratio of 2.93, but holds a debt-to-equity ratio of 157.53.
$ARDX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Ardelyx, Inc.
There were several insider transactions on May 21, 2026. President & CEO Michael Raab sold 54,748 shares at an average price of $6.27. Other executives, including Chief Commercial Officer Eric Duane Foster and Chief Patient Officer Laura Williams, also sold shares on the same date.
About Ardelyx, Inc.
Ardelyx, Inc., headquartered in Waltham, Massachusetts, is a biotechnology company specializing in the discovery, development, and commercialization of therapies for unmet medical needs. Notably, it offers IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in chronic kidney disease patients on dialysis. The company was founded in 2007 and is led by CEO Michael G. Raab.
Bottom Line
Ladenburg Thalmann's recent upgrade to a 'buy' rating with a $16 target reflects a positive outlook on Ardelyx, Inc. Investors often track such analyst upgrades for insights into potential stock performance. However, it's important to remember that these ratings are based on past and present data, which may not predict future results.
Get Ardelyx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.